Flaws Of ‘Virtual’ Advisory Committees Highlighted At Aducanumab Panel

 
• By Ramsey Baghdadi

The intensely negative advisory committee for Biogen’s proposed Alzheimer’s therapy was a shocker. Would it have happened if US FDA had been able to convene an in-person event instead of a ‘virtual’ one?

Is it easier to give an application the thumbs down over Adobe Connect? • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers